http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 63 reviews. 63 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

R - LOC

Choose a suitable interchangeable generic or brand drug, if you could not find the prescribed medicine.
We do not sell drugs. This site contains prices only for information purposes to help you buy drugs cheaply.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

R - LOC uses and description

Sort by popularity
R - LOC - Used for: Treating certain conditions that cause your body to make too much stomach acid (eg, Zollinger-Ellison syndrome). It is also used to treat ulcers of the small intestine that have not responded to other treatment. It may be used as a short-term alternative to oral ranitidine, in patients who are not able to take medicine by mouth. It may also be used for other conditions as determined by your doctor.

R - LOC is an H receptors, particularly those in gastric parietal cells, leading to inhibition of gastric acid secretion.

Indication: Treatment and maintenance therapy of duodenal ulcer; management of gastroesophageal reflux disease (GERD; including erosive or ulcerative disease); short-term treatment of benign gastric ulcer; treatment of pathologic hypersecretory conditions (Zollinger-Ellison); maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers; treatment of endoscopically diagnosed erosive esophagitis; maintenance of healing of erosive esophagitis.

OTC

Treatment and prevention of heartburn.

Unlabeled Uses

Prevention of upper GI bleeding; treatment of aspiration pneumonia; stress ulcer; and gastric NSAID damage. Used as a part of a multi-drug regimen to eradicate Helicobacter pylori in the treatment of peptic ulcer; protection against aspiration of acid during anesthesia; prevention of gastroduodenal mucosal damage that may be associated with long-term NSAIDs; control of acute upper GI bleeding; prevention of stress ulcers.

Blocker of histamine H2-receptors. Inhibits basal and stimulated by histamine, gastrin and acetylcholine (to a lesser extent) the secretion of hydrochloric acid. Increases the pH of gastric contents and reduces the activity of pepsin. The duration of action of R - LOC with a single admission - 12 hours.

R - LOC is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

R - LOC is in a group of drugs called histamine-2 blockers. R - LOC works by reducing the amount of acid the stomach produces.

R - LOC is used to treat and prevent ulcers in the stomach and intestines. It also treats conditions in which the stomach produces too much acid, such as Zollinger-Ellison syndrome. R - LOC also treats gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn.

R - LOC is a gastric medicine. It is used to treat conditions caused by excessive acidity in your stomach, such as stomach ulcers and reflux disease (also known as "heartburn", in which food or acid from your stomach backs up into your mouth, leaving a sour or bitter taste). R - LOC can also be used to relieve stomach irritation and ulceration caused by certain painkillers such as non-steroidal anti-inflammatory drugs (NSAIDs). R - LOC treats these conditions by reducing the amount of acid your stomach makes.

Oral Benign gastric and duodenal ulceration

Adult: Initially, 300 mg as a single daily dose at bedtime or 150 mg bid; 300 mg bid for 4 wk may be used in duodenal ulcer to improve healing). Treatment duration: 4-8 wk for benign gastric and duodenal ulceration; up to 8 wk in NSAID-associated ulceration. For prevention of NSAID-associated ulceration: 150 mg bid.

Child: 3-12 yr: 2-4 mg/kg (max: 150 mg) bid for 4-8 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral H.pylori infection

Adult: 300 mg once daily or 150 mg bid in combination with amoxicillin 750 mg tid and metronidazole 500 mg tid given for 2 wk. Treatment with R - LOC may be continued for a further 2 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Gastro-oesophageal reflux disease

Adult: 150 mg bid or 300 mg at bedtime for up to 8 wk, may increase to 150 mg four times daily for 12 wk in severe cases.

Child: 5-10 mg/kg daily, given in 2 divided doses. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Hypersecretory conditions

Adult: Initially, 150 mg bid/tid increased to 6 g daily if necessary. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Acid aspiration during general anaesthesia

Adult: 150 mg given 2 hr before induction of anaesthesia and preferably, an additional dose on the previous evening. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Dyspepsia

Adult: 75 mg repeated if necessary up to 4 doses daily. Max: 2 wk of continuous use at each time. For chronic episodic dyspepsia: 150 mg bid for up to 6 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Parenteral Prophylaxis of acid aspiration during general anaesthesia

Adult: 50 mg IV/IM given 45-60 minutes before the induction of anaesthesia. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Doses should be halved. Intravenous Hypersecretory conditions

Adult: Initially, 1 mg/kg/hr IV infusion, may increase by increments of 0.5 mg/kg/hr starting after 4 hr if necessary. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Intravenous Stress ulceration of upper gastrointestinal tract

Adult: 50 mg by slow IV Inj as priming dose followed by 125-250 mcg/kg/hr as continuous IV infusion then transfer to oral dose of 150 mg bid once oral feeding is resumed. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved.

Indications:

Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. For prevention of NSAID-associated ulceration: 150 mg bid. Eradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ R - LOC for a further 2 wk. GERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed. Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. Chronic episodic dyspepsia 150 mg twice daily for up to 6 wk. Short-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. Prophylaxis during NSAID treatment 150 mg twice daily. IV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. IV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.

Oral Benign gastric and duodenal ulceration

Adult: Initially, 300 mg as a single daily dose at bedtime or 150 mg bid for at least 4 wk. For duodenal ulcer, 300 mg bid may be used.

Child: 2-4 mg/kg bid. Max dose: 300 mg in 24 hr. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Eradication of H. pylori infection

Adult: 300 mg once daily or 150 mg bid in combination with amoxicillin 750 mg tid and metronidazole 500 mg tid given for 2 wk. Treatment with R - LOC may be continued for a further 2 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Gastroesophageal reflux disease with or without oesophagitis including erosions and ulcerations

Adult: 150 mg bid or 300 mg at bedtime for up to 8 wk, may increase to 150 mg four times daily for 12 wk in severe cases.

Child: 5-10 mg/kg daily, given in 2 divided doses. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Pathological hypersecretory conditions e.g. Zollinger-Ellison syndrome

Adult: Initially, 150 mg bid/tid increased to 6 g daily if necessary. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral acid aspiration during general anaesthesia

Adult: 150 mg given 2 hr before induction of anaesthesia and preferably, an additional dose on the previous evening. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Chronic episodic dyspepsia

Adult: 150 mg bid for 6 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Short-term symptomatic dyspepsia

Adult: 75 mg repeated if necessary up to 4 doses daily. Max dose: 2 wk of continuous use at each time. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Prophylaxis against duodenal ulceration during NSAID treatment

Adult: 150 mg bid. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Intravenous Pathological hypersecretory conditions e.g. Zollinger-Ellison syndrome

Adult: Initially, 1 mg/kg/hr IV infusion, may increase by increments of 0.5 mg/kg/hr starting after 4 hr if necessary. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Intravenous Stress ulceration of upper GI tract

Adult: 50 mg by slow IV Inj as priming dose followed by 125-250 mcg/kg/hr as continuous IV infusion then transfer to oral dose of 150 mg bid once oral feeding is resumed. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Parenteral acid aspiration during general anaesthesia

Adult: 50 mg IV/IM given 45-60 min before the induction of anaesthesia. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Doses should be halved.

Oral Benign gastric and duodenal ulceration

Adult: Initially, 300 mg as a single daily dose at bedtime or 150 mg bid; 300 mg bid for 4 wk may be used in duodenal ulcer to improve healing). Treatment duration: 4-8 wk for benign gastric and duodenal ulceration; up to 8 wk in NSAID-associated ulceration. For prevention of NSAID-associated ulceration: 150 mg bid.

Child: 3-12 yr: 2-4 mg/kg (max: 150 mg) bid for 4-8 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral H.pylori infection

Adult: 300 mg once daily or 150 mg bid in combination with amoxicillin 750 mg tid and metronidazole 500 mg tid given for 2 wk. Treatment with R - LOC may be continued for a further 2 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Gastro-oesophageal reflux disease

Adult: 150 mg bid or 300 mg at bedtime for up to 8 wk, may increase to 150 mg four times daily for 12 wk in severe cases.

Child: 5-10 mg/kg daily, given in 2 divided doses. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Hypersecretory conditions

Adult: Initially, 150 mg bid/tid increased to 6 g daily if necessary. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Acid aspiration during general anaesthesia

Adult: 150 mg given 2 hr before induction of anaesthesia and preferably, an additional dose on the previous evening. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Oral Dyspepsia

Adult: 75 mg repeated if necessary up to 4 doses daily. Max: 2 wk of continuous use at each time. For chronic episodic dyspepsia: 150 mg bid for up to 6 wk. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Parenteral Prophylaxis of acid aspiration during general anaesthesia

Adult: 50 mg IV/IM given 45-60 minutes before the induction of anaesthesia. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Doses should be halved. Intravenous Hypersecretory conditions

Adult: Initially, 1 mg/kg/hr IV infusion, may increase by increments of 0.5 mg/kg/hr starting after 4 hr if necessary. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Intravenous Stress ulceration of upper gastrointestinal tract

Adult: 50 mg by slow IV Inj as priming dose followed by 125-250 mcg/kg/hr as continuous IV infusion then transfer to oral dose of 150 mg bid once oral feeding is resumed. Renal impairment: Dosage reduction is required in severe renal impairment. CrCl (ml/min) Dosage Recommendation ≤20 Dosage should be halved. Special Populations: Adjust dose in patients with renal impairment: 150 mg/day orally or 25 mg for parenteral administration.

Treatment and maintenance therapy of duodenal ulcer; management of gastroesophageal reflux disease (GERD; including erosive or ulcerative disease); short-term treatment of benign gastric ulcer; treatment of pathologic hypersecretory conditions (Zollinger-Ellison); maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers; treatment of endoscopically diagnosed erosive esophagitis; maintenance of healing of erosive esophagitis. OTCTreatment and prevention of heartburn.

Active ingredients: Ranitidine
Unit description, dosagePrice, USD
R - LOC Capsule/ Tablet / 150mg (10 units)$ 0.10
R - LOC Injection / 50mg (2ml units)$ 0.05

List of r - loc brand and generic drugs

R-Loc (Ethiopia, India, Myanmar, Thailand)
Tablets; Oral; Ranitidine Hydrochloride 150 mg
Rabiodina
Radan
Raden (Japan)
Radin (Hong Kong, Indonesia)
Radin 150 mg x 5 x 6's$ 5.36
Radin 50 mg/2 mL x 5's$ 7.65
Injectable; Injection; Ranitidine Hydrochloride 25 mg / ml
Tablets, Film-Coated; Oral; Ranitidine Hydrochloride 150 mg
Radina (Argentina, Nicaragua)
Radinat (Ecuador)
Radine (Philippines)
Radine 150 mg x 100's
Radyn
Ramadine (Philippines)
Ramadine 5% w/v T-SOLN / 500ml
Ramitab
Tablet, Film-Coated; Oral; Ranitidine 75 mg
Tablets, Film-Coated; Oral; Ranitidine 75 mg
Ran
Ran H2
Ran Lich
Tablet, Film-Coated; Oral; Ranitidine Hydrochloride 150 mg
Tablet, Film-Coated; Oral; Ranitidine Hydrochloride 300 mg
Tablets, Film-Coated; Oral; Ranitidine Hydrochloride 150 mg
Tablets, Film-Coated; Oral; Ranitidine Hydrochloride 300 mg
Ran X
Ran X 150mg TAB / 10$ 0.35
Ran- X
Ran- X 150mg TAB / 10$ 0.35
Ranacid (Oman)
Ranaps
Ranbex (Bangladesh)
RANCER (India)
RANCER Capsule/ Tablet / 300mg (10 units)$ 0.16
RANCER Capsule/ Tablet / 150mg (10 units)$ 0.09
150 mg x 10's$ 0.09
300 mg x 10's$ 0.16
Rancer 150mg TAB / 10$ 0.09
Rancer 300mg TAB / 10$ 0.16
Rancus (Indonesia)
Rancus 150 mg x 10 x 10's$ 35.70
Randec
Randec Ranitidine 150mg,Dicyclomine10mg TAB / 20$ 0.44
Randil (Dominican Republic)
Randin (Philippines)
Randin (amp) 25 mg/1 mL x 2 mL x 10's
Random
Random Ranitidine 150mg,Domperidone10mg TAB / 10
Randon
Randon Ranitidine 150mg,Domperidone10mg TAB / 10$ 0.30
Ranee
Ranee 150mg TAB / 10$ 0.13
Ranee 300mg TAB / 10$ 0.23
Ranee D
Ranee D Ranitidine 150mg,Domperidone10mg TAB / 10$ 0.42
Ranee D Ranitidine 150mg, Domperidone10mg TAB / 10$ 0.42

Show all R - LOC generic names
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer